ERBB2 and breast carcinoma: We previously showed that in extracranial models of HER2 + breast cancer, resistance to HER2-targeted therapy in HER2 + breast cancer is mediated by upregulation of cyclin D1 and CDK4, thus, susceptible to CDK4/6 inhibition4.